Provided by Tiger Trade Technology Pte. Ltd.

Vor Biopharma Inc.

12.51
+0.38003.13%
Post-market: 12.600.0900+0.72%19:58 EST
Volume:3.40M
Turnover:44.13M
Market Cap:274.10M
PE:-0.04
High:14.13
Open:12.00
Low:11.77
Close:12.13
52wk High:65.80
52wk Low:2.62
Shares:21.91M
Float Shares:18.97M
Volume Ratio:0.35
T/O Rate:17.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-342.6591
EPS(LYR):-34.0333
ROE:-125.43%
ROA:-144.27%
PB:-0.12
PE(LYR):-0.37

Loading ...

Dec 09, 2025

Major Issues Report

Form 8-K - Current report
Nov 13, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 12, 2025

Major Issues Report

Form 8-K - Current report
Nov 03, 2025

Major Issues Report

Form 8-K - Current report
Oct 28, 2025

Major Issues Report

Form 8-K - Current report
Oct 20, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 20, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 16, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 16, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 15, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 15, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 24, 2025

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Sep 17, 2025

Major Issues Report

Form 8-K - Current report
Sep 03, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 02, 2025

Major Issues Report

Form 8-K - Current report
Aug 27, 2025

Major Issues Report

Form 8-K - Current report
Aug 27, 2025

Major Issues Report

Form 8-K - Current report
Aug 12, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]